Attovia Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	1.8	1.35	-
Revenue Growth	-	-	-
Cost of Revenue	64.26	54.15	33.86
Gross Profit	-62.46	-52.8	-33.86
Selling, General & Admin	13.59	14.36	7.69
Operating Expenses	13.73	14.36	7.69
Operating Income	-76.19	-67.16	-41.55
Interest & Investment Income	5.93	6.63	3.44
Other Non Operating Income (Expenses)	-0.11	-0.1	-1.69
Pretax Income	-70.38	-60.63	-39.8
Net Income	-70.38	-60.63	-39.8
Net Income to Common	-70.11	-60.63	-39.8
Net Income Growth	-	-	-
Shares Outstanding (Basic)	4	4	4
Shares Outstanding (Diluted)	4	4	4
Shares Change	-	11.84%	-
EPS (Basic)	-17.01	-15.35	-11.27
EPS (Diluted)	-17.01	-15.35	-11.27
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-68.22	-61.51	-36.81
Free Cash Flow Per Share	-16.55	-15.57	-10.42
Operating Margin	-4232.94%	-4974.74%	-
Profit Margin	-3894.94%	-4490.89%	-
Free Cash Flow Margin	-3790.11%	-4556.44%	-
EBITDA	-75.25	-66.36	-41.24
D&A For EBITDA	0.94	0.8	0.31
EBIT	-76.19	-67.16	-41.55
Revenue as Reported	1.8	1.35	-

SEC Filings: 10-K · 10-Q